Received for publication May 4, 2006.
Revised June 14, 2006.
Accepted for publication June 15, 2006.

USING A TRITIATED COMPOUND TO ELUCIDATE ITS PRECLINICAL METABOLIC AND EXCRETORY PATHWAYS IN VIVO: EXPLORING TRITIUM EXCHANGE RISK

Abstract

The metabolism and excretion of N-(3R)-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide (1), an agonist of the ₇ nicotinic acetylcholinergic receptor, were determined in both Sprague-Dawley rats and beagle dogs using [³H]1. Initially, 3-tritio-furanopyridine 1 ([³H]1a) was evaluated in pilot mass balance studies by determining total radioactivity recovery and pharmacokinetics in lyophilized excreta and non-lyophilized plasma, respectively. Lower mass balance and much greater circulatory radioactivity exposures were observed in rats than in dogs, with urinary tritiated water (HTO) only detected in rats. The 133 h half-life in rats, possibly due to very slowly eliminated metabolites, was more likely attributable to HTO formed from [³H]1a due to site-specific chemical and/or metabolic ³H-instability, which was confirmed by urinary HTO. Contrastingly, dog data supported ³H-stability within [³H]1a. Conflicting cross-species data with [³H]1a suggested species-specific metabolic fates for 1 requiring a ³H-form of 1 resistant to ³H-loss in rats. Accordingly, tritiation of 1 at its furanopyridine C₇, a site predicted to be both chemically and metabolically stable, yielded [³H]1b, which allowed in both species the determination of all excretory pathways, total radioactivity pharmacokinetics, and major excretory and circulatory metabolites with complete radioactivity recovery without HTO generation. Definitive metabolite elucidation for 1 using [³H]1b confirmed the suspected species-dependent metabolic susceptibility for ³H-loss from [³H]1a in rats, but not dogs, as the majority of rat metabolites resulted from furanopyridine biotransformation. The described studies explore the evaluation of tritium exchange risk from a mechanistic biotransformation perspective and highlight the need for careful deliberation when considering and designing ³H-compounds for radiolabeled metabolism studies.

Key words: analytical chemistry, drug clearance, drug development, mass spectrometry, metabolite identification, pharmacokinetics, reactive intermediate, structure elucidation

This article has been cited by other articles:

				C. L. Shaffer, M. Gunduz, R. J. Scialis, and A. F. Fang Metabolism and Disposition of a Selective {alpha}7 Nicotinic Acetylcholine Receptor Agonist in Humans Drug Metab. Dispos., July 1, 2007; 35(7): 1188 - 1195. [Abstract] [Full Text] [PDF]